In line with these studies, genomic NGS profiling of over 100 patients with multiple types of advanced recurrent, metastatic or refractory sarcomas found that they harbored mutations in TYK2, JAK1, JAK2, and JAK3 [21]. This evidence concerns the gene TYK2 and sarcoma.